Molecular Partners AG (MOLN)
4.17
+0.40
(+10.76%)
USD |
NASDAQ |
May 03, 16:00
4.17
0.00 (0.00%)
After-Hours: 19:41
Molecular Partners Profit Margin (Quarterly): -1.92K% for Dec. 31, 2023
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -1.92K% |
| September 30, 2023 | -450.2% |
| June 30, 2023 | -3.85K% |
| March 31, 2023 | -484.5% |
| December 31, 2022 | -647.2% |
| September 30, 2022 | -570.0% |
| June 30, 2022 | -38.49% |
| Date | Value |
|---|---|
| March 31, 2022 | 88.63% |
| December 31, 2021 | -1.01K% |
| September 30, 2021 | -349.0% |
| June 30, 2021 | -529.5% |
| March 31, 2021 | -2.03K% |
| December 31, 2020 | -1.40K% |
| September 30, 2020 | -5.81K% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
-5.81K%
Minimum
Sep 2020
88.63%
Maximum
Mar 2022
-1.36K%
Average
-608.6%
Median
Profit Margin (Quarterly) Benchmarks
| AC Immune SA | -32.05% |
| CRISPR Therapeutics AG | 44.67% |
| Addex Therapeutics Ltd | -1.86K% |
| NLS Pharmaceutics Ltd | -- |
| MoonLake Immunotherapeutics | -- |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -30.00% |
| Return on Assets | -26.93% |
| Return on Invested Capital | -30.00% |
| Operating Margin (Quarterly) | -1.61K% |
| Return on Net Operating Assets | -149.9% |